To improve tolerance and adherence for PI3K/AKT/mTOR inhibitors, oncology nurses should preemptively provide patients with tools like loperamide for diarrhea and non-drowsy antihistamines for rash, instructing them to use them at the very first sign of symptoms.

Broad-spectrum RAS-on inhibitors like daraxonrasib present skin toxicity as a dose-limiting side effect. However, this rash is clinically distinct from that caused by EGFR inhibitors. It is often manageable with brief treatment interruptions, frequently without requiring dose reductions, and patients tend to acclimate to it over time.

A subgroup analysis from Capitello-291 suggests patients treated with capivasertib in the first-line setting experienced less diarrhea and rash than those in later lines. This aligns with a broader trend where heavily pre-treated patients exhibit poorer drug tolerance. This finding supports considering potent targeted agents earlier in the treatment sequence to potentially improve tolerability and outcomes.

When using the AKT inhibitor capivasertib, preventing rash is more effective than treating it. A recommended strategy for physicians unfamiliar with the drug is to prescribe twice-daily non-drowsy antihistamines proactively for the first 6-8 weeks, as the rash is difficult to manage once it appears.

The side effect profile of capivasertib is front-loaded. Key toxicities like diarrhea and rash appear quickly, leading to the majority (63%) of drug discontinuations occurring within the first three months. This highlights a critical window for proactive management and patient education to improve adherence.

Data from the SOLAR-1 trial showed that adding prophylactic antihistamines for patients taking alpelisib cut the incidence of all-grade rash in half and reduced high-grade rash by 40%. This has become a standard practice for mitigating dermatologic toxicity with this class of drugs.

While guidelines recommend any second-generation antihistamine for rash prophylaxis, clinical data indicate cetirizine is more effective than others for histamine-mediated cutaneous events caused by drugs. Clinicians should preferentially recommend cetirizine unless a patient has a known preference or intolerance.

The AKT inhibitor capivasertib has a unique and complex dosing schedule (twice daily, four days on, three days off). This necessitates providing patients, especially the elderly, with specific tools like dosing diaries to prevent confusion and ensure adherence.

Over 90% of patients on the new RAS inhibitor diraxin rasib develop a skin rash. The standard protocol involves prophylactic antibiotics like doxycycline, started *before* the first drug dose and continued for at least eight weeks, to mitigate this toxicity.